Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria

Malaria Clinical Trial

Official title:

A Phase III Randomised, Double-blind, Double-dummy, Comparative Study to Assess the Safety and Efficacy of Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children and Adult Patients in Korea With Acute P. Vivax Malaria

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04368910
• Other study ID #: SP-C-008-07
• Status: Terminated
• Phase: Phase 3
• Start date: September 6, 2007
• Est. completion date: November 15, 2010

Study information

• Verified date: November 2021
• Source: Medicines for Malaria Venture
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this clinical study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (180:60 mg) with that of standard chloroquine therapy in children and adults with acute, uncomplicated Plasmodium vivax (P. vivax) malaria

Description:

This is a multi-centre, randomised, double-blind, double-dummy, parallel group, comparative trial. It is a Phase III study designed to meet the regulatory requirements for registration of pyronaridine artesunate (PA) in Korea. Chloroquine will be used as a comparator, which is recognized as an effective and well-tolerated anti-malarial therapy, and is standard blood-stage therapy for patients with P. vivax malaria in Korea. This study will be conducted in a total of 40 male and female children (≥20 kg body weight) and adult patients suffering from acute symptomatic uncomplicated P. vivax malaria recruited from study sites in Korea.

Patients will be randomised in a 1:1 ratio to receive either oral PA (180:60-mg tablets) plus chloroquine-placebo or oral chloroquine (155 mg tablets) plus PA-placebo, once a day for 3 consecutive days (Days 0, 1, and 2). For PA, posology will be based on body weight ranges, with patients receiving 1 to 4 tablets per day depending on their body weight. The actual dose range covered by this regimen is 7.2:2.4 mg/kg to 13.8:4.6 mg/kg per day, which has been shown to be effective and safe in Phase I and II studies. The chloroquine daily dose is 10 mg/kg on Days 0 and 1 and 5 mg/kg on Day 2 for children and 620 mg on Days 0 and 1 and 310 mg on Day 2 for adults.

Patients will be confined to the study facility for ≥4 days (Days 0, 1, 2, and 3) and remain near the study site for ≥7 days, or once fever and parasite clearance has been confirmed for ≥24 hours - whichever occurs later.

The primary efficacy end point for the study is the crude cure rate on Day 14. Scheduled follow-up visits will continue until completion of the study at Day 42. In the case of adverse events reported and unresolved at Day 42, patients will be followed up for a further 30 days, or until resolution of the event.

It is anticipated that the study results will be pooled with the results of study SP-C-006-06 entitled "A Phase III Comparative (Double-blind, Double-dummy) Randomized Multicentre Study to Assess the Safety & Efficacy of Oral Pyronaridine Artesunate (180:60 mg) Versus Chloroquine (155 mg) in Children & Adult Patients with Acute Vivax Malaria " for a formal non-inferiority analysis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 30
• Est. completion date: November 15, 2010
• Est. primary completion date: October 16, 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Male or female patients between the age of 3 and 60 years, inclusive.

2. Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.

3. Presence of acute uncomplicated P. vivax mono-infection confirmed by:

1. Fever, as defined by axillary/tympanic temperature =37.5°C or oral/rectal temperature =38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,

2. Positive microscopy of P. vivax with parasite density =250/ µL of blood (including at least 50% of asexual parasites).

4. Written informed consent, in accordance with local practice, provided by patient and/or parent/guardian/spouse. If the patient is unable to write, witnessed consent is permitted according to local ethical considerations.

5. Ability to swallow oral medication.

6. Ability and willingness to participate based on information given to patient or parent or guardian and access to health facility.

Exclusion Criteria:

1. Presence of a mixed Plasmodium infection.

2. Presence of other clinical condition requiring hospitalization.

3. Presence of significant anaemia, as defined by Hb <8 g/dL.

4. Known history or evidence of clinically significant disorders such as cardiovascular (including arrhythmia, QTc interval greater than or equal to 450 msec), respiratory (including active tuberculosis), hepatic, renal, gastrointestinal, immunological (including active HIV-AIDS), neurological (including auditory), endocrine, infectious, malignancy, psychiatric or other abnormality (including recent head trauma).

5. Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, chloroquine or artesunate or other artemisinins.

6. Known history of hypersensitivity, allergic or adverse reactions to chloroquine, primaquine and related agents.

7. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).

8. Known seropositive HIV antibody.

9. Have received any antimalarial treatment in the preceding 2 weeks, as determined by history and, whenever feasible, by screening test.

10. Have received antibacterial with known antimalarial activity in the preceding 2 weeks.

11. Have received any investigational drug within the past 4 weeks.

12. Liver function tests (AST/ALT levels) >2.5 times the upper limit of normal range.

13. Known significant renal impairment as indicated by serum creatinine levels of >1.4 mg/dL.

14. Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.

15. Previous participation in the present clinical trial with pyronaridine artesunate.

Related Conditions & MeSH terms

• Malaria
• Malaria, Vivax

Intervention

Drug:
• Pyronaridine - artesunate
Oral pyronaridine artesunate (180:60 mg tablets), plus chloroquine-placebo once a day for 3 consecutive days.
• Chloroquine
Oral chloroquine (155 mg tablets), plus pyronaridine artesunate-placebo, once a day for 3 consecutive days.

Locations

Country	Name	City	State
Korea, Republic of	Inje University Ilsan Paik Hospital	Goyang-si
Korea, Republic of	Eulji General Hospital	Seoul

Sponsors (2)

Lead Sponsor	Collaborator
Medicines for Malaria Venture	Shin Poong Pharmaceuticals

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Crude Cure Rate on Day 42	Proportion of subjects with crude cure rate at Day 42, defined as absence of parasitaemia on Day 42, irrespective of body temperature without previously meeting any of the criteria of treatment failure	Day 42
Primary	Crude Cure Rate on Day 14	Percentage of subjects with crude cure rate at Day 14, defined as absence of parasitaemia on Day 14, irrespective of body temperature without previously meeting any of the criteria of treatment failure	Day 14
Secondary	Crude Cure Rate on Day 28	Percentage of subjects with crude cure rate at Day 28, defined as absence of parasitaemia on Day 28, irrespective of body temperature without previously meeting any of the criteria of treatment failure	Day 28
Secondary	Parasite Clearance Time (PCT)	Parasite clearance time is defined as the time from first dosing to the time of first blood draw with parasite clearance. Parasite clearance was defined as zero presence of asexual parasites for 2 consecutive negative readings taken between 7 and 25 hours apart	Days 0, 3, 7, 14, 21, 28, 35, and 42 (or on any other day if the subject spontaneously returned within the 42-day period)
Secondary	Fever Clearance Time (FCT)	Fever clearance time is defined as the time from first dosing to the first normal reading of temperature for 2 consecutive normal temperature readings taken between 7 and 25 hours apart	Day 0 and every 8 hours over =72 hours following first study drug administration or temperature normalization for =2 readings between 7 and 25 hours apart, then at each visit (Days 7, 14, 28 and 42)
Secondary	Percentage of Patients Who Had Cleared Parasite on Days 1, 2, and 3	Parasite clearance is defined as at least 2 consecutive negative smears for asexual parasites obtained within an interval of 7 to 25 hours post-dosing	Days 1, 2, and 3
Secondary	Percentage of Patients Who Had Cleared Fever on Days 1, 2, and 3	Fever clearance is defined as at least 2 consecutive normal body temperature measurements (<37.5 C axillary/tympanic or <38.0 C oral/rectal) obtained within an interval of 7 to 25 hours postdosing	Days 1, 2, and 3
Secondary	Number of Participants With Adverse Events (AEs)	Number of Participants with AEs, including clinically significant laboratory results, electrocardiogram (ECG), vital signs or physical examination abnormalities	Day 0 to 42. Subjects experiencing AEs at Day 42 were followed for up to 30 days after the end of study